Skip to main content

September 2015 Vol 8, No 6

The Continuing Clinical and Economic Burden of Cardiometabolic Health

Dalia Buffery, MA, ABD

Compensation for Managing Population Health

David B. Nash, MD, MBA

Longitudinal Commercial Claims–Based Cost Analysis of Diabetic Retinopathy Screening Patterns

Kathryn Fitch, RN, MEd, Thomas Weisman, MD,MBA, Tyler Engel, ASA, MAAA, Adam Turpcu, PhD, Helen Blumen, MD, MBA, Yamina Rajput, MS, Purav Dave, MS, MBA

Stakeholder Perspective

The Economics of Screening Patients with Diabetes for Diabetic Retinopathy

by Sharon Glave Frazee, PhD, MPH

Evaluating Drug Cost per Response with SGLT2 Inhibitors in Patients with Type 2 Diabetes Mellitus

Janice M.S. Lopez, PharmD, MPH, Brian Macomson, PharmD, Varun Ektare, MPH, Dipen Patel, PhD, Marc Botteman, MSc

Stakeholder Perspective

Evaluating the Benefits and Cost of the Sodium-Glucose Cotransporter 2 Inhibitors

by Quang T. Nguyen, DO, FACE, FTOS

The Impact of HbA1c Testing on Total Annual Healthcare Expenditures Among Newly Diagnosed Patients with Diabetes

Prajakta Bhounsule, MS, Andrew M. Peterson, PharmD, PhD

Stakeholder Perspective

Saving Money Is Not Always the Objective

by Gary M. Owens, MD

Entresto (Sacubitril/Valsartan): First-in-Class Angiotensin Receptor Neprilysin Inhibitor FDA Approved for Patients with Heart Failure

Results 1 - 6 of 6